Bausch Health(BHC) - 2022 Q4 - Earnings Call Transcript

On January 31, the US Patent and Trademark Office issued an additional US patent that protects XIFAXAN-550 product for the treatment of IBS-D and expires in February 2029. The patent is now Orange Book listed for the XIFAXAN-550 product and further supports our XIFAXAN patent portfolio. We remain confident in the strength of the XIFAXAN patents. This is all we are prepared to say about the XIFAXAN litigation at this time. We are investing in new sales force capabilities to enhance effectiveness, leveraging ...